Patents by Inventor Charles R. Manclark

Charles R. Manclark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hybridomas and resulting monoclonal antibodies directed against antigens of Bordetella pertussis
    Patent number: 5162223
    Abstract: A panel of monoclonal antibody (Mab) producing hybridomas directed against various antigens of Bordetella pertussis are disclosed herein. The hybridomas and the antigens that the resulting monoclonals are directed against include: (1) BPG10F8C3 and BPE8D8B1--lipooligosaccharide A (LOS A), serotype 1; (2) BPD5, BPE6, and BPF2--fimbriae, serotype 2; (3) BPE3, BPE8 and BPD8--69 kDa nonfimbrial protein, serotype 3; and (4) BPB7, BPC10, BPD4, BPD6, BPD9, and BPF5--fimbriae, serotype 6.
    Type: Grant
    Filed: February 17, 1989
    Date of Patent: November 10, 1992
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Resources
    Inventors: Michael J. Brennan, Charles R. Manclark, Zhong Ming Li
  • Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
    Patent number: 5101014
    Abstract: The present invention comprises a method for the purification of the 69 kDa outer membrane protein of Bordetella B. pertussis and the protein purified therewith. A preferred embodiment comprises the purification of the 69 kDa protein from Bordetella B. pertussis strain Bp 353. The present process is advantageous in that it does not require or involve the use of biologics (such as monoclonal antibodies) and therefore simplifies the purification procedure and makes the resulting purified protein particularly advantageous for inclusion in acellular vaccines.
    Type: Grant
    Filed: February 10, 1989
    Date of Patent: March 31, 1992
    Assignee: United States of America
    Inventors: Drusilla L. Burns, Michael J. Brennan, Jeanine L. Gould-Kostka, Charles R. Manclark
  • Process for isolation of the B oligomer of pertussis toxin
    Patent number: 4845036
    Abstract: A method for dissociating the B oligomer of pertussis toxin comprising incubating pertussis toxin in an aqueous solution of urea, sodium phosphate buffer, and a nucleotide selected from the group consisting of ATP and ADP, and optional zwitterionic detergent; applying the incubated solution to a CM-Sepharose column; and eluting the B oligomer from the column with potassium phosphate buffer containing urea.
    Type: Grant
    Filed: February 3, 1987
    Date of Patent: July 4, 1989
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Drusilla L. Burns, Charles R. Manclark